C . C . Honeycutt et al .: J Extra Corpor Technol 2023 , 55 , 159 – 166 165
13 . McQueen CA ( 2003 ) Neonatal ontogeny of murine arylamine N-acetyltransferases : implications for arylamine genotoxicity . Toxicolog Sci 73 ( 2 ), 279 – 86 .
14 . Nakamura AT , Btaiche IF , Pasko DA , Jain JC , Mueller BA ( 2004 ) In vitro clearance of trace elements via continuous renal replacement therapy . J Ren Nutr 14 ( 4 ), 214 – 9 .
15 . Watt KM , Cohen-Wolkowiez M , Williams DC , Bonadonna DK , Cheifetz IM , Thakker D , et al . ( 2017 ) Antifungal extraction by the extracorporeal membrane oxygenation circuit . J Extra Corpor Technol 49 ( 3 ), 150 – 9 .
16 . Wildschut ED , Ahsman MJ , Allegaert K , Mathot RAA , Tibboel D ( 2010 ) Determinants of drug absorption in different ECMO circuits . Intensive Care Med 36 ( 12 ), 2109 – 16 .
17 . Dzierba AL , Abrams D , Brodie D ( 2017 ) Medicating patients during extracorporeal membrane oxygenation : the evidence is building . Crit Care 21 ( 1 ), 66 .
18 . Shekar K , Roberts JA , Mcdonald CI , Ghassabian S , Anstey C , Wallis SC , et al . ( 2015 ) Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit : results from an ex vivo study . Crit Care 14 ( 19 ), 164 .
19 . Sherwin J , Heath T , Watt K ( 2016 ) Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation : A Review of the Current Literature . Clin Ther 38 ( 9 ), 1976 – 94 .
20 . Zamoner W , de Freitas FM , Garms DSS , de Oliveira MG , Balbi AL , Ponce D ( 2016 ). Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients . Pharmacolo Res Perspect 4 ( 6 ), e00280 .
21 . Pea F , Viale P , Pavan F , Furlanut M ( 2007 ) Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy . Clin Pharmacokinet 46 ( 12 ), 997 – 1038 .
22 . Ulldemolins M , Vaquer S , Llauradó-Serra M , Pontes C , Calvo G , Soy D , et al . ( 2014 ) Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy . Crit Care 18 ( 3 ), 227 .
23 . Cies JJ , Nikolos P , Moore WS , Giliam N , Low T , Marino D , et al . ( 2022 ) Oxygenator impact on meropenem / vaborbactam in extracorporeal membrane oxygenation circuits . Perfusion , 37 ( 7 ), 729 – 37 .
24 . Bakdach D , Elajez R , Bakdach AR , Awaisu A , De Pascale G , Ait Hssain A ( 2022 ) Pharmacokinetics , pharmacodynamics , and dosing considerations of novel b-lactams and b-lactam / b-lactamase inhibitors in critically ill adult patients : focus on obesity , augmented renal clearance , renal replacement therapies , and extracorporeal membrane oxygenation . J Clin Med 11 ( 23 ), 6898 .
25 . Gijsen M , Dreesen E , Annaert P , Nicolai J , Debaveye Y , Wauters J , et al . ( 2021 ) Meropenem pharmacokinetics and target attainment in critically ill patients are not affected by extracorporeal membrane oxygenation : a matched cohort analysis . Microorganisms 9 ( 6 ), 1310 .
26 . Shekar K , Roberts JA , Ghassabian S , Mullany DV , Wallis SC , Smith MT , et al . ( 2013 ) Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation : cause for concern ? J Antimicrob Chemother 68 ( 3 ), 726 – 7 .
27 . Shekar K , Fraser JF , Taccone FS , Welch S , Wallis SC , Mullany DV , et al . ( 2014 ) The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics : a matched cohort study . Crit Care 18 ( 6 ), 565 .
28 . Donadello K , Antonucci E , Cristallini S , Roberts JA , Beumier M , Scolletta S , et al . ( 2015 ) b-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy : A case – control study . Int J Antimicrob Agents 45 ( 3 ), 278 – 82 .
29 . Shekar K , Roberts JA , Mcdonald CI , Fisquet S , Barnett AG , Mullany DV , et al . ( 2012 ) Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation . Crit Care 16 ( 5 ), R194 .
30 . Bilgrami I , Roberts JA , Wallis SC , Thomas J , Davis J , Fowler S , et al . ( 2010 ) Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration . Antimicrob Agents Chemother 54 ( 7 ), 2974 – 8 .
31 . Ulldemolins M , Soy D , Llaurado-Serra M , Vaquer S , Castro P , Rodríguez AH , et al . ( 2015 ) Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy : influence of residual diuresis on dose requirements . Antimicrob Agents Chemother 59 ( 9 ), 5520 – 8 .
32 . Li L , Li X , Xia Y , Chu Y , Zhong H , Li J , et al . ( 2020 ) Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy . Front Pharmacol 11 , 786 .
33 . Smith PB , Cohen-Wolkowiez M , Castro LM , Poindexter B , Bidegain M , Weitkamp JH , et al . ( 2011 ) Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections . Pediatr Infect Dis J 30 ( 10 ), 844 – 9 .
34 . Scharf C , Paal M , Schroeder I , Vogeser M , Draenert R , Irlbeck M , et al . ( 2020 ) Therapeutic drug monitoring of meropenem and piperacillin in critical illness – experience and recommendations from one year in routine clinical practice . Antibiotics ( Basel ) 9 ( 3 ), 131 .
35 . Bulik CC , Fauntleroy KA , Jenkins SG , Abuali M , LaBombardi VJ , Nicolau DP , et al . ( 2010 ) Comparison of meropenem mics and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods . J Clin Microbiol 48 ( 7 ), 2402 – 6 .
36 . Saito J , Shoji K , Oho Y , Aoki S , Matsumoto S , Yoshida M , et al . ( 2020 ) Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis : a case report . J Glob Antimicrob Resist 1 ( 22 ), 651 – 5 .
37 . Jang SM , Infante S , Abdi Pour A ( 2020 ) Drug dosing considerations in critically ill patients receiving continuous renal replacement therapy . Pharmacy ( Basel ) 8 ( 1 ), 18 .
38 . Mouton JW , van den Anker JN ( 1995 ) Meropenem clinical pharmacokinetics . Clin Pharmacokinet 28 ( 4 ), 275 – 86 .
39 . Moon YSK , Chung KC , Gill MA ( 1997 ) Pharmacokinetics of meropenem in animals , healthy volunteers , and patients . Clin Infect Dis 1 , 24 ( Supplement _ 2 ), S249 – 55 .
40 . Preston TJ , Ratliff TM , Gomez D , Olshove VF , Nicol KK , Sargel CL , et al . ( 2010 ) Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit . J Extra Corpor Technol 42 ( 3 ), 199 – 202 .
41 . Williams DC , Turi JL , Hornik CP , Bonnadonna DK , Williford WL , Walczak RJ , et al . ( 2015 ) Circuit oxygenator contributes to extracorporeal membrane oxygenation-lnduced hemolysis . ASAIO J 61 ( 2 ), 190 – 5 .
42 . Imburgia CE , Rower JE , Green DJ , Mcknite AM , Kelley WE , Reilly CA , et al . ( 2022 ) Remdesivir and GS-441524 extraction by ex vivo extracorporeal life support circuits . ASAIO J 68 ( 9 ), 1204 .
43 . Póvoa P , Moniz P , Pereira JG , Coelho L ( 2021 ) Optimizing antimicrobial drug dosing in critically ill patients . Microorganisms 9 ( 7 ), 1401 .